Rhythm Drug Patent Portfolio
Rhythm owns 1 orange book drug protected by 3 US patents Given below is the list of Rhythm's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11129869 | Pharmaceutical compositions | 04 Jul, 2034 | Active |
| US8039435 | Melanocortin receptor ligands | 13 Oct, 2027 | Active |
| US9458195 | Melanocortin receptor ligands | 13 Oct, 2027 | Active |
Latest Legal Activities on Rhythm's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Rhythm.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Mar, 2024 | US9458195 |
|
FDA Final Eligibility Letter
Critical
| 10 May, 2023 | US9458195 |
|
FDA Final Eligibility Letter
Critical
| 10 May, 2023 | US8039435 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Apr, 2023 | US8039435 |
| transaction for FDA Determination of Regulatory Review Period | 01 Jul, 2022 | US9458195 |
| transaction for FDA Determination of Regulatory Review Period | 01 Jul, 2022 | US8039435 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jun, 2022 | US8039435 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jun, 2022 | US9458195 |
| Second letter to regulating agency to determine regulatory review period | 13 Jan, 2022 | US8039435 |
| Second letter to regulating agency to determine regulatory review period | 13 Jan, 2022 | US9458195 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Sep, 2021 | US11129869 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Sep, 2021 | US11129869 |
| Sequence Moved to Public Database | 28 Sep, 2021 | US11129869 |
|
Email Notification
Critical
| 09 Sep, 2021 | US11129869 |
|
Issue Notification Mailed
Critical
| 08 Sep, 2021 | US11129869 |
Rhythm Drug Patents' Oppositions Filed in EPO
Rhythm drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 18, 2021, by Sandoz Ag. This opposition was filed on patent number EP14724574A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP14724574A | May, 2021 | SANDOZ AG | Granted and Under Opposition |
Rhythm's Family Patents
Rhythm Drug List
Given below is the complete list of Rhythm's drugs and the patents protecting them.
1. Imcivree
Imcivree is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11129869 | Pharmaceutical compositions |
04 Jul, 2034
(9 years from now)
| Active |
| US8039435 | Melanocortin receptor ligands |
13 Oct, 2027
(2 years from now)
| Active |
| US9458195 | Melanocortin receptor ligands |
13 Oct, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Imcivree's drug page